The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / NIH Starts Study of COVID-19 Booster Shot in People with Autoimmune Diseases

NIH Starts Study of COVID-19 Booster Shot in People with Autoimmune Diseases

August 31, 2021 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—The U.S. National Institutes of Health (NIH) is testing a booster shot of COVID-19 vaccines in people with autoimmune diseases who have not responded well to the primary vaccine course.

You Might Also Like
  • People with Rheumatic Diseases Should Pay Extra Attention to Self-Care During COVID-19
  • NIH Director Addresses Gathering of Experts on Autoimmune Diseases
  • Researchers Explore Response to COVID-19 Vaccines in the Elderly

The mid-stage study will be conducted among about 600 participants aged 18 and above who have been fully vaccinated with shots from either Pfizer Inc., Moderna Inc. or Johnson & Johnson.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

U.S. regulators earlier in the month authorized a third dose of COVID-19 vaccines by Pfizer and Moderna for people with compromised immune systems, as concerns mounted about infections among such populations.

“Many people who have an autoimmune disease that requires immunosuppressive therapy have had a poor immune response to the authorized and approved COVID-19 vaccines, placing these individuals at high risk for the disease,” says Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, in a statement.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

An estimated 8% of Americans have an autoimmune disease, which occurs when the body’s immune system attacks healthy cells, tissues and organs.

Participants in the NIH trial will receive an extra dose of the vaccine that was originally administered to them, and the study will record how many of them have a better antibody response four weeks after the booster shot.

The trial will initially include people with one of five autoimmune diseases, including multiple sclerosis and rheumatoid arthritis, with early results expected in November.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. NIH launches study of extra COVID-19 vaccine dose in people with autoimmune disease. U.S. National Institutes of Health. 2021 Aug 27.

Filed Under: Conditions Tagged With: booster shot, COVID-19, National Institutes of Health (NIH), NIH, vaccine

You Might Also Like:
  • People with Rheumatic Diseases Should Pay Extra Attention to Self-Care During COVID-19
  • NIH Director Addresses Gathering of Experts on Autoimmune Diseases
  • Researchers Explore Response to COVID-19 Vaccines in the Elderly
  • Cohort Study Reveals Patients Treated with Rituximab Have Poorer COVID-19 Outcomes

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)